Resource Logo
CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update

UNITED STATES: Potential for Risky Sex Spurs Discord on HIV Prevention Pill


Bloomberg News (05.09.12) - Thursday, May 10, 2012

AIDS advocates are divided about whether the potential approval of the first pill to prevent HIV infection will advance public health efforts to curb the epidemic.

The Food and Drug Administration is considering whether to approve Gilead Sciences Inc.'s Truvada for groups at high risk of HIV infection. A study cited by FDA shows it can reduce the risk of HIV by up to 94 percent for people who took the pill as prescribed. However, other trials indicated just 10 percent of participants adhered to prescribing instructions, and one study was halted after no benefit was seen. The $14,000-a-year drug is already approved for treating HIV infection.

"Among our own patients who are HIV-positive, we have difficulty getting them to adhere, let alone people who don't have the disease," said AIDS Healthcare Foundation President Michael Weinstein. AHF provides medical care for 130,000 patients worldwide.

Some advocates worry Truvada's approval could encourage unprotected sex. "If you have this new option, would you be riskier? There is no evidence to show that might be the case, but that doesn't mean it's not a concern," said Mitchell Warren, executive director of AVAC: Global Advocacy for HIV Prevention.

James Loduca, spokesperson for the San Francisco AIDS Foundation, said approving Truvada as a pre-exposure prophylaxis would help certain people avoid infection during particular times in their lives. "We don't think PrEP is a lifetime prevention tool," he said. "It would be used in a targeted way for specific population and in relatively short periods of time." "If deployed correctly and efficiently, it could make a big dent in the epidemic in the US," said Howard Jaffe, president and chair of the Gilead Foundation.


Copyright © 2012 -CDC Prevention News Update, Publisher. All rights reserved to Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

Information in this article was accurate in May 10, 2012. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.